Clinical trial · Interventional
IDO2 Genetic Status Informs the Neoadjuvant Efficacy of Chloroquine (CQ) in Brain Metastasis Radiotherapy
IDO2 Genetic Status Informs the Neoadjuvant Efficacy of Chloroquine in Brain Metastasis Radiotherapy.
NCT01727531CI-TRIAL-00017430completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This research is being done to determine if a short course of Chloroquine (five weeks) before, during and after whole brain radiation therapy (WBRT) will improve the overall survival of subjects being treated for brain metastases.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Metastasis | Brain Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Chloroquine diphosphate | Drug | Chloroquine | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- CQ Arm
- description
- 250 mg chloroquine once a day by mouth beginning one week prior to beginning radiation therapy and continue for a total of five weeks.
- interventionNames
- Drug: Chloroquine diphosphate
Primary outcomes (1)
- measure
- Specific Aim
- timeFrame
- up to 24-months after completion of treatment
- description
- Determine patients physical profiles prior WBRT and at regular intervals afterwards up to 24 months after radiotherapy
Secondary outcomes (1)
- measure
- Secondary endpoint: death
- timeFrame
- up to 24 months after completion of treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with histologically confirmed primary solid malignancy * Patients with single or multiple brain metastases * Patients with metastasis diameter \< 5 cm * Age \> 18 * Clearance from the patient's physician that treatment with chloroquine should not pose a problem to the patient Exclusion Criteria: * Patients with a history of hypotension, cardiomyopathy, epilepsy, seizures * Patients with impaired renal function * Patients with psoriasis, porphyria * Patients with known hypersensitivity to 4-aminoquinoline compounds * Pregnancy, nursing * Prior radiotherapy * During the chloroquine treatment, patients complaining from visual or auditory disturbances, and patients suffering from acute gastrointestinal problems i.e. Anorexia, nausea, vomiting, diarrhea, abdominal cramps
References
Publications (0)
Data not yet available
No reference posted for this study.